Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New COPD drug given marketing authorisation

  • 1 Comment

The European Commission has licensed umeclidinium (Incruse) as a once-daily, maintenance bronchodilator treatment to relieve the symptoms of chronic obstructive pulmonary disease.

The long-acting muscarinic antagonist comes in a 55mcg strength inhalation powder and is intended to be delivered with the Ellipta inhaler.

Manufacturer GlaxoSmithKline said it expected that the first launches of the drug would have taken place in Europe by the end of 2014.

  • 1 Comment

Readers' comments (1)

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs